Wasdell Group granted HPRA licence at new EU headquarters

24 Jan 2019

The new Irish facility will allow the company to continue to act as a gateway to Europe for its British and North American customers.

The Wasdell Group has been granted its Health Products Regulatory Authority (HPRA) licence for its new EU headquarters in Dundalk, Ireland.

Wasdell Group granted HPRA licence at new EU headquarters

Following a successful HPRA inspection in December 2018, the company - an outsourcing partner for companies in the pharmaceutical and clinical trials industries - is now certified to conduct Qualified Person (QP) batch certification and release of pharmaceutical products to Europe ahead of the facility commencing operations in Spring 2019.

Colin Newbould, Director of Regulatory Affairs and QP services at The Wasdell Group said: “Being accredited with this licence ahead of schedule is testament to our team.

“While this expansion will allow us to cater for increased customer demand, the Dundalk facility is also an integral part of our proactive contingency plan to protect our customers critical supply chains ahead of the UK’s exit from the European Union (EU).

“Receiving the HPRA licence is an important milestone, bringing us closer to finalising what has been a huge project for us. And, with the 29th March Brexit deadline just around the corner, it means our customers can be confident that we can manage any risk associated no matter the outcome.”

The €30-million investment into the Ireland facility was made in 2018 and forms part of the company’s ongoing plans to expand its offering outside of the UK.

The Dundalk facility will offer a full range of contract services including quality control (QC) import testing and batch release for pharmaceutical products, as well as a variety of current and novel packaging technologies. It will also house the company’s largest storage and distribution facilities to date.

Vincent Dunne, CEO of The Wasdell Group said: “With almost 75% of our turnover being a result of export business and a growing customer base in both the Irish and US markets, Dundalk was a logical choice for our EU headquarters.

“The new facility will allow us to continue to act as a gateway to Europe for our British and North American customers.”

The Irish facility comes as the latest phase in the company’s strategic plan to bolster capabilities and capacity, following the recent £500K investment into its new microbiological and analytical laboratory at its Newcastle, UK site.

Read More

Related news

Pharmapack Europe 2019 Award Winners

Pharmapack Europe 2019 Award Winners

7 Feb 2019

Awards showcased a wide range of industry-changing discoveries in drug delivery, packaging and automation.

Read more 
Brexit - the EU FMD's painful problem

Brexit - the EU FMD's painful problem

7 Feb 2019

Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.

Read more 
New series of advanced freeze dryers

New series of advanced freeze dryers

6 Feb 2019

The LyoConstellation series allows the development of highly aggressive cycles and the mapping of the furthest reaches of theoretical design space for a formulation.

Read more 
Hitachi Chemical to acquire apceth Biopharma

Hitachi Chemical to acquire apceth Biopharma

5 Feb 2019

Acquisition will strengthen Hitachi's presence in the second-largest cell and gene therapy market in the world.

Read more 
FDA approves first generic Advair Diskus

FDA approves first generic Advair Diskus

4 Feb 2019

Mylan's Wixela Inhub is the first FDA-approved therapeutically equivalent generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for certain patients with asthma or COPD.

Read more 
Sartorius joins the community of the National Institute for Innovation in Manufacturing Biopharmaceuticals

Sartorius joins the community of the National Institute for Innovation in Manufacturing Biopharmaceuticals

3 Feb 2019

Company hopes to contribute substantially to further optimizing and accelerating the current manufacturing processes in the biopharmaceutical industry.

Read more 
Particle Sciences partners with Encube Ethicals to develop novel vaginal rings

Particle Sciences partners with Encube Ethicals to develop novel vaginal rings

31 Jan 2019

The partnership will focus on rings for the administration of existing approved drugs, improving drug effectiveness and patient compliance.

Read more 
Manufacturing consultancy up 150% as life sciences prepare for a digital future

Manufacturing consultancy up 150% as life sciences prepare for a digital future

30 Jan 2019

Increasing appetite for digitised manufacturing and using data to improve GMP manufacturing.

Read more 
SGS expands testing capabilities at its Glasgow facility

SGS expands testing capabilities at its Glasgow facility

29 Jan 2019

Clients will benefit from a fully comprehensive range of validated biosafety methods to support cell bank and viral vaccine manufacturing and lot release of drug product.

Read more 
UK and Russia sign MoU on regulatory co-operation on medicines

UK and Russia sign MoU on regulatory co-operation on medicines

29 Jan 2019

Medicines regulators of the UK and Russian set out key principles to support their collaboration on improving public health.

Read more